AnaptysBio, Inc. (ANAB) News
Follow AnaptysBio, Inc. (ANAB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
FDA Approves AnaptysBio-Discovered Drug for Rectal Cancer
The FDA granted accelerated approval to Jempezi, a drug discovered by AnaptysBio. Shares gained 5.8% to $49.31 in Monday afternoon trading.
REGULATION | Oct 19, 2026, 07:08 PM UTC
M
FDA Approves Jemperli for Locally Advanced Rectal Cancer
GSK received U.S. FDA approval for Jemperli (dostarlimab) for adults with MSI-H/dMMR locally advanced rectal cancer.
REGULATION | Oct 19, 2026, 06:24 PM UTC
L
Jemperli approved in the U.S. for certain rectal cancer patients
Jemperli (dostarlimab) was approved in the U.S. for adults with MSI-H/dMMR locally advanced rectal cancer, described as the first and only immunotherapy for this indication.
REGULATION | Oct 19, 2026, 06:18 PM UTC
L
Weekly Recap: AZUR-1 primary endpoint hit and Jemperli rights dispute
AnaptysBio, Inc. (NASDAQ:ANAB) reported AZUR-1 met its 12—month primary endpoint and will show data at ESMO Oct 25, 2026, while the company pursues reversal of Jemperli rights in an Oct 20, 2026 hearing as it balances ri
NEWS | Sep 28, 2026, 11:05 AM UTC
L
AnaptysBio Price Target Maintained With a $95.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 02:40 PM UTC
L
AnaptysBio Is Maintained at Outperform by Leerink Partners
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 01:27 PM UTC
L
Leerink Partners maintains Outperform rating on AnaptysBio, $81 price target
Leerink Partners maintained their Outperform rating on AnaptysBio's stock with a price target of $81.00.The price target implies an upside of 50.2% from the Sep 22 close of $53.92.Key takeaways from the analyst noteStron
EQUITY | Sep 23, 2026, 01:17 PM UTC
M
AnaptysBio reports Q2 and FY2026 transitional financial results
AnaptysBio, Inc. announced second quarter and transitional fiscal year 2026 financial results and provided a business update.
EQUITY | Sep 21, 2026, 10:10 PM UTC
M
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties
AnaptysBio said Q2 collaboration revenue increased as Jemperli royalties rose, per its press release.
EQUITY | Sep 21, 2026, 08:26 PM UTC
M
AnaptysBio reports Q2 FY26 results; Jemperli and Quimilza milestones flagged
AnaptysBio reported Q2 FY26 results. It said Jemperli is showing year-over-year growth, with potential FDA actions and a litigation judgment expected within 6 months. The company also said it expects an FDA decision for
EQUITY | Sep 21, 2026, 08:21 PM UTC
M
AnaptysBio reports 2Q EPS of $5.11
TradingView News reports AnaptysBio 2Q EPS of $5.11 for ANAB.
EARNINGS | Sep 21, 2026, 08:17 PM UTC
M
AnaptysBio reports 2Q revenue of $27.5M
TradingView News says AnaptysBio 2Q revenue was $27.5M.
EARNINGS | Sep 21, 2026, 08:17 PM UTC
L
ANAB - Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
ANAB - Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
EARNINGS | Sep 21, 2026, 08:15 PM UTC
L
ANaptysBio to announce Q2'26 results September 11
AnaptysBio, Inc. (ANAB) is set to announce its Q2'26 results on September 11. The results are expected to be disclosed at 8:00 AM ET (12:00 PM UTC), with revenue expected at 8.89 million and EPS estimated at (0.47) USD.
EARNINGS | Sep 10, 2026, 11:00 AM UTC
L
AnaptysBio CFO Chris Murphy scheduled to present at H.C. Wainwright conference
AnaptysBio said Chris Murphy, its CFO, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 01, 2026, 08:17 PM UTC
L
Anaptys to participate in H.C. Wainwright 28th annual global conference
Anaptys (ANAB) says it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 01, 2026, 08:15 PM UTC
L
ANAB Ongoing Dostarlimab Litigation Supportive of ANAB Claims @ Piper
ANAB Ongoing Dostarlimab Litigation Supportive of ANAB Claims @ Piper
EQUITY | Jul 21, 2026, 01:00 PM UTC